The history of GeNeuro


  • Finalization of the recruitment of patients in the study of Phase IIb CHANGE-MS in sclerosis, ahead of the schedule, and launch of the ANGEL-MS study also funded by Servier, allowing all patients who finished the Phase IIb study CHANGE-MS to extend their treatment for two years.
  • GeNeuro Announces treatment of the first patient in a Phase IIa study with GNbAC1 in type 1 diabetes. This Australian clinical trial plans to recruit 60 adult patients in more than 10 centers.
  • GeNeuro signs an agreement with the U.S. NIH to develop a new treatments against Amyotrophic Lateral Sclerosis. This partnership focuses on antibodies targeting the HERV-K, a potential cause of disease.


  • GeNeuro's IPO on Euronext Paris, raising 33 M€ in order to expedite its clinical development in the United States and in new indications, such as type-1 diabetes.
  • GeNeuro Announces treatment of first patients in its study of phase IIb in MS. The CHANGE-MS clinical trial, funded by Servier, targets a-260 patient recruitment in 13 European countries.


  • GeNeuro SA launches a Phase IIb trial in multiple sclerosis.
  • GeNeuro SA announces the completion of a pharmacology study testing high doses of GNbAC1.



  • The Swiss Medicine Agency authorizes GeNeuro to undertake a Phase IIa trial with a repeated-dose extension for a total of 12 months.
  • GeNeuro SA announces the completion of a phase IIa clinical trial with GNbAC1. During the study, MS patients received the monoclonal antibody GNbAC1 at two different doses.
  • GeNeuro confirms the scientific interest in developing GNbAC1 as a treatment for CIDP during a scientific advice meeting with the European Medicines Agency (EMA).


  • GeNeuro SA announces the launch of a Phase IIa clinical study with GNbAC1. The randomized placebo-controlled Phase IIa study tested single ascending doses of GNbAC1 in patients with multiple sclerosis for the first time.


  • GeNeuro SA announces the completion of its Phase I clinical study with GNbAC1. The randomized, double-blind, placebo-controlled, Phase I study of single ascending intravenous doses of GNbAC1 in healthy volunteers demonstrated that GNbAC1 is well tolerated.
  • Swissmedic, the Swiss medicines agency, authorizes GeNeuro to start a Phase I trial of the monoclonal antibody GNbAC1 in healthy volunteers. GNbAC1 is developed for the treatment of multiple sclerosis.
  • GeNeuro's 5th anniversary.


  • GeNeuro obtains a positive opinion from a German regulatory scientific committee, the Paul Ehrlich Institute, regarding the pre-clinical package for its lead monoclonal antibody GNbAC1, a humanized monoclonal antibody targeting a human endogenous retrovirus, to treat multiple sclerosis.
  • GeNeuro Innovation SAS obtains the status of Small and Medium Enterprise (SME) awarded by the European Medicines Agency.
  • GeNeuro Innovation SAS opens a laboratory facility in Archamps.en Haute Savoie (France).


  • GeNeuro SA moves to its new location in Geneva / Plan-les-Ouates (Switzerland).
  • The French subsidiary GeNeuro Innovation SAS is established in Lyon (France).


  • In August 2008, GeNeuro obtains funding from Eclosion and Institut Mérieux to expand its operations and advance its drug portfolio towards clinical development.


  • GeNeuro SA is founded by Dr Hervé Perron, Dr Christophe Mérieux and Jesús Martin-Garcia, with the help of bioMérieux, a leading French diagnostics company, and Eclosion, a Swiss start-up incubator that supports the development of projects in life sciences.